International Stem Cell announced that it intends to start the phase 1/2a clinical study of its cell therapy for the treatment of Parkinson's disease in Australia within the next few months. The company has completed the required preclinical studies for the phase 1/2a clinical study of the clinical product, ISC-hpNSC, for the treatment of Parkinson's disease. This TGA submission includes non-clinical studies evaluating the safety and tolerability of the clinical product, ISC-hpNSC, in different animal species, including non-human primates, along with the chemistry and manufacturing controls and a summary of the clinical study design, according to the company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1134 USD | +117.66% |
|
+88.69% | +82.90% |
1st Jan change | Capi. | |
---|---|---|
+82.90% | 9L | |
+18.97% | 4.53TCr | |
+41.98% | 4.04TCr | |
-10.06% | 3.79TCr | |
+31.15% | 3.18TCr | |
-7.79% | 2.77TCr | |
+13.32% | 2.65TCr | |
+43.05% | 1.4TCr | |
+31.28% | 1.24TCr | |
-7.41% | 1.13TCr |
- Stock Market
- Equities
- ISCO Stock
- News International Stem Cell Corporation
- International Stem Cell to Launch Start the Phase 1/2a Clinical Study of its Cell Therapy